2.55
Redhill Biopharma Ltd Adr (RDHL) 最新ニュース
RedHill Biopharma targets UK approval for H. pylori therapy - Investing.com India
RedHill Biopharma targets UK approval for H. pylori therapy By Investing.com - Investing.com South Africa
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline By Investing.com - Investing.com South Africa
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline - Investing.com
What Did We Note About Insider Trading At Redhill Biopharma Ltd. ADR (NASDAQ: RDHL)? - Stocks Register
Hyloris secures global rights to RedHill’s RHB-102 - Investing.com India
Redhill Biopharma stock hits 52-week low at $4.79 - Investing.com India
Earnings call transcript: RedHill Biopharma Q1 2022 sees revenue dip - Investing.com
RedHill tests opaganib with Bayer's drug in prostate cancer study By Investing.com - Investing.com South Africa
RedHill tests opaganib with Bayer's drug in prostate cancer study - Investing.com India
RedHill stock rises on expanded Medicare coverage - Investing.com
RedHill stock rises on expanded Medicare coverage By Investing.com - Investing.com South Africa
GAMMA Investing LLC Buys 595 Shares of ArcelorMittal S.A. (NYSE:MT) - Defense World
RedHill wins $8 million judgment in New York court - Investing.com India
RedHill Biopharma: FDA Accepts TALICIA’s NDA - Investing.com
COVID-19 Competitive Landscape 2024 (Updated) - openPR
BARDA funds RedHill's opaganib for Ebola treatment - Investing.com
Medi-Cal extends Talicia access for 15 million Californians - Investing.com
Redhill Biopharma stock hits 52-week high of $8.03 amid volatility - Investing.com
RedHill Biopharma Announces Positive Obesity and Diabetes Results with Opaganib - Investing.com
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire
symbol__ Stock Quote Price and Forecast - CNN
Balancing Acidity: Exploring the Proton Pump Inhibitors Market - openPR
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034 - PR Newswire
Peptic Ulcer Drugs Market Drivers Analysis | CAGR of 3.5% - Market.us
Benign Growth For RedHill Biopharma Ltd. (NASDAQ:RDHL) Underpins Stock's 41% Plummet - Yahoo Finance
Cathie Wood Predictions 2022 - New Trader U
RedHill Biopharma Stock: Looking At An Unexciting Dead-End (NASDAQ:RDHL) - Seeking Alpha
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D - PR Newswire
RedHill Gets Nod in Brazil for Coronavirus Study on Opaganib - Yahoo Finance
AstraZeneca divestment of Movantik to RedHill Biopharma completed - AstraZeneca
The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement - Yahoo Finance
RedHill Biopharma to Focus Commercial Efforts on Talicia® - GlobeNewswire
RedHill Biopharma: TALICIA Launch For H. Pylori In Sight - Investing.com
RedHill Biopharma's Drug Pipeline May Merit Substantial Upside, And Potential Catalysts Are On The Horizon - Seeking Alpha
RedHill Biopharma files for further Nasdaq offering - גלובס
RedHill Biopharma (RDHL) Stock Price, News & Analysis - MarketBeat
大文字化:
|
ボリューム (24 時間):